Deprenyl: protective vs. symptomatic effect.
Kofman
O S
OS
Department of Medicine (Neurology), University of Toronto, Ontario, Canada.
D015632:1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine / Q000009:adverse effects / Q000031:analogs & derivatives; D002986:Clinical Trials as Topic; D006801:Humans; D020267:MPTP Poisoning; D010300:Parkinson Disease / Q000188:drug therapy* / Q000517:prevention & control; D012642:Selegiline / Q000627:therapeutic use*
D012642:Selegiline; D015632:1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine